Alexander Fitzpatrick Sells Shares of SPRY $SPRY

Key Points

  • Alexander Fitzpatrick sold 3,355 shares of ARS Pharmaceuticals, Inc. ($SPRY) worth $33,550.
  • $SPRY last traded around $9.76.

Alexander Fitzpatrick, Chief Legal Officer at ARS Pharmaceuticals, Inc. ($SPRY), sold 3,355 shares at an average price of $10.00, for a total transaction of $33,550. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

ARS Pharmaceuticals, Inc. ($SPRY) Stock

Last price$9.76
Market cap$969.20M
Forward P/E-10.19
Beta0.83
52-week low$6.66
52-week high$18.90
50-day MA$8.44
200-day MA$9.43
Current ratio4.94
Quick ratio4.64
Debt-to-equity2.79

ARS Pharmaceuticals, Inc. Earnings

EPS (ttm)$-2.00
Revenue (ttm)$98.99M
Revenue growth184.5%
Net margin-200.0%
Return on equity-136.4%
Next earningsAug 13, 2026

Analysts Set New Price Targets

ConsensusStrong Buy
Average target$28.80
High target$32.00
Low target$25.00
Analysts covering5

About ARS Pharmaceuticals, Inc.

ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.

ExchangeNasdaqGM
SectorHealthcare
IndustryBiotechnology
HeadquartersSan Diego, CA
CEOMr. Richard E. Lowenthal M.B.A., M.S., MSMSEL
Employees154

See Also

This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.